SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-22-000138
Filing Date
2022-07-22
Accepted
2022-07-22 16:15:58
Documents
15
Period of Report
2022-07-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20220720.htm   iXBRL 8-K 44872
2 EX-10.1 zentalis-2022employmentind.htm EX-10.1 135566
3 EX-10.2 zentalis-formofstockoption.htm EX-10.2 42385
4 EX-10.3 zentalis-formofrsuagreemen.htm EX-10.3 41840
  Complete submission text file 0001725160-22-000138.txt   452307

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20220720.xsd EX-101.SCH 1902
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20220720_lab.xml EX-101.LAB 24849
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20220720_pre.xml EX-101.PRE 13046
9 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20220720_htm.xml XML 11259
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 221100112
SIC: 2834 Pharmaceutical Preparations